Hantz Financial Services’s TG Therapeutics TGTX Stock Holding History

Hantz Financial Services’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$297K	Buy	5,404 +995	+23%	+$40.7K	﹤0.01%	940
2026 Q1	$146K	Buy	4,409 +3,172	+256%	+$94.5K	﹤0.01%	1117
2025 Q4	$37K	Buy	1,237 +560	+83%	+$18.3K	﹤0.01%	1556
2025 Q3	$24K	Buy	677 +211	+45%	+$6.95K	﹤0.01%	1503
2025 Q2	$17K	Buy	466 +144	+45%	+$5.36K	﹤0.01%	1335
2025 Q1	$13K	Buy	+322	New	+$10.8K	﹤0.01%	913

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Hantz Financial Services's TGTX Position: Q2 2026 in Review

Hantz Financial Services increased its TG Therapeutics (TGTX) stake by 23% in Q2 2026, buying an estimated $40.7K and bringing the position to 5,404 shares worth $297K. The position accounts for ﹤0.01% of the portfolio, ranked #940.

Hantz Financial Services first reported a position in TGTX in Q1 2025 and has held it in 6 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Hantz Financial Services held 5,404 shares of TG Therapeutics worth $297K as of Q2 2026.
Hantz Financial Services bought 995 TG Therapeutics shares in Q2 2026, an estimated $40.7K.
TG Therapeutics made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #940 holding.
Hantz Financial Services first reported a position in TG Therapeutics in Q1 2025 and has held it in 6 quarters since.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.